Journal article : Review
Diagnosis and treatment of postpartum haemorrhage: a race against time
- Abstract:
- Postpartum haemorrhage (PPH) is common, affecting an estimated 13% of women having vaginal birth and 31% of women having caesarean birth. Successful management of PPH requires early and accurate diagnosis and effective treatment. A systematic review found that subjective visual estimation of blood loss misses 52% of PPH diagnoses at vaginal birth (pooled sensitivity 48%, 95% CI 44-53), and probably more at caesarean birth. The WHO-International Federation of Gynecology and Obstetrics-International Confederation of Midwives consolidated guidelines on PPH therefore recommend objective quantification of blood loss with products such as a calibrated blood collection drape. When supported by a robust implementation strategy and a first-response treatment bundle, objective measurement of blood loss and monitoring of vital signs has been shown to diagnose PPH accurately and early, and improve clinical outcomes. Refractory PPH can progress to life-threatening PPH, which should be managed by a multidisciplinary team providing aggressive resuscitation and targeted treatment. Saving the life of a woman with excessive postpartum bleeding is a race against time. The six delays to avoid are: (1) in the diagnosis (by use of objective cumulative blood loss measurement and early trigger criteria), (2) in the first-response treatment (by authorising midwives to administer all components of a standardised bundle of interventions), (3) in the escalation (by use of explicit escalation criteria and red flags), (4) in the use of temporising measures (eg, non-pneumatic anti-shock garment), (5) in the identification and targeted management of any specific causes of bleeding, and (6) in the provision of blood and blood products. Quick actions to avoid these delays can mean the difference between life and death for a woman with PPH.
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Accepted manuscript, pdf, 955.6KB, Terms of use)
-
- Publisher copy:
- 10.1016/s0140-6736(26)01031-7
Authors
+ Gates Foundation
More from this funder
- Funder identifier:
- https://ror.org/0456r8d26
- Grant:
- INV-092837
+ United Nations Development Programme
More from this funder
- Funder identifier:
- https://ror.org/051777d98
- Publisher:
- Elsevier
- Journal:
- Lancet More from this journal
- Volume:
- 408
- Issue:
- 10549
- Pages:
- 83-92
- Place of publication:
- England
- Publication date:
- 2026-06-12
- Acceptance date:
- 2026-05-20
- DOI:
- EISSN:
-
1474-547X
- ISSN:
-
0140-6736
- Pmid:
-
42285120
- Language:
-
English
- Keywords:
- Subtype:
-
Review
- Pubs id:
-
2434512
- Local pid:
-
pubs:2434512
- Source identifiers:
-
W7164564236
- Deposit date:
-
2026-10-04
- ARK identifier:
Terms of use
- Copyright holder:
- Elsevier Ltd.
- Copyright date:
- 2026
- Rights statement:
- © 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
- Notes:
- The author accepted manuscript (AAM) of this paper has been made available under the University of Oxford's Open Access Publications Policy, and a CC BY public copyright licence has been applied.
- Licence:
- CC Attribution (CC BY)
If you are the owner of this record, you can report an update to it here: Report update to this record